1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Hyperphosphatemia Global Clinical Trials Review, H2, 2015

Hyperphosphatemia Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Hyperphosphatemia Global Clinical Trials Review, H2, 2015" provides an overview of Hyperphosphatemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Hyperphosphatemia Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hyperphosphatemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Hyperphosphatemia 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Hyperphosphatemia Therapeutics Clinical Trials 31
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Bayer AG 33
Clinical Trial Overview of Bayer AG 33
Astellas Pharma Inc. 35
Clinical Trial Overview of Astellas Pharma Inc. 35
Shire Plc 37
Clinical Trial Overview of Shire Plc 37
Sanofi 38
Clinical Trial Overview of Sanofi 38
Mitsubishi Chemical Holdings Corporation 39
Clinical Trial Overview of Mitsubishi Chemical Holdings Corporation 39
AstraZeneca Plc 40
Clinical Trial Overview of AstraZeneca Plc 40
Galenica Ltd. 41
Clinical Trial Overview of Galenica Ltd. 41
Ardelyx, Inc. 42
Clinical Trial Overview of Ardelyx, Inc. 42
Amgen Inc. 43
Clinical Trial Overview of Amgen Inc. 43
Clinical Trial Overview of Top Institutes / Government 44
Washington University School of Medicine 44
Clinical Trial Overview of Washington University School of Medicine 44
All India Institute of Medical Sciences 45
Clinical Trial Overview of All India Institute of Medical Sciences 45
Arak University of Medical Sciences 46
Clinical Trial Overview of Arak University of Medical Sciences 46
Brigham and Women's Hospital 47
Clinical Trial Overview of Brigham and Women's Hospital 47
CKD-MBD Clinical Study Group 48
Clinical Trial Overview of CKD-MBD Clinical Study Group 48
COLC Study Research group 49
Clinical Trial Overview of COLC Study Research group 49
Denver Nephrology 50
Clinical Trial Overview of Denver Nephrology 50
Islamic Azad University of Tabriz 51
Clinical Trial Overview of Islamic Azad University of Tabriz 51
Juntendo University 52
Clinical Trial Overview of Juntendo University 52
Juntendo University School of Medicine 53
Clinical Trial Overview of Juntendo University School of Medicine 53
Five Key Clinical Profiles 54
Appendix 107
Abbreviations 107
Definitions 107
Research Methodology 108
Secondary Research 108
About GlobalData 109
Contact Us 109
Disclaimer 109
Source 110

List of Tables
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Region, 2015* 7
Hyperphosphatemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Hyperphosphatemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Hyperphosphatemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Hyperphosphatemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Hyperphosphatemia Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Hyperphosphatemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Hyperphosphatemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials, G7 Countries (%), 2015* 15
Hyperphosphatemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Hyperphosphatemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials, E7 Countries (%), 2015* 18
Hyperphosphatemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Hyperphosphatemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Hyperphosphatemia Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Hyperphosphatemia Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Hyperphosphatemia Therapeutics, Global, Withdrawn Clinical Trials, 2015* 25
Hyperphosphatemia Therapeutics, Global, Terminated Clinical Trials, 2015* 26
Hyperphosphatemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Hyperphosphatemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
Hyperphosphatemia Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Hyperphosphatemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Hyperphosphatemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2015* 33
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2015* 35
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2015* 37
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2015* 38
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Mitsubishi Chemical Holdings Corporation, 2015* 39
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 40
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Galenica Ltd., 2015* 41
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ardelyx, Inc., 2015* 42
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2015* 43
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2015* 44
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2015* 45
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Arak University of Medical Sciences, 2015* 46
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Brigham and Women's Hospital, 2015* 47
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by CKD-MBD Clinical Study Group, 2015* 48
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by COLC Study Research group, 2015* 49
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Denver Nephrology, 2015* 50
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Islamic Azad University of Tabriz, 2015* 51
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Juntendo University, 2015* 52
Hyperphosphatemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Juntendo University School of Medicine, 2015* 53

List of Figures
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Hyperphosphatemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Hyperphosphatemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Hyperphosphatemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Hyperphosphatemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Hyperphosphatemia Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Hyperphosphatemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Hyperphosphatemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials, G7 Countries (%), 2015* 15
Hyperphosphatemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Hyperphosphatemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Hyperphosphatemia to Nutritional Disorders Clinical Trials, E7 Countries (%), 2015* 18
Hyperphosphatemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Hyperphosphatemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Hyperphosphatemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Hyperphosphatemia Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Hyperphosphatemia Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Hyperphosphatemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Hyperphosphatemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
Hyperphosphatemia Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Hyperphosphatemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Hyperphosphatemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.